Family II

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics

Retrieved on: 
Tuesday, March 28, 2023
Psilocybin, Intellectual property, CSE, Depression, Drug development, MSET, Pharmacokinetics, DSM-IV codes, FSE, Research, LSD, Thermoregulation, Development, Patient, Family II, Contract research organization, Drug discovery, Family 1, Therapy, IND, Family, Pharmacology, Safety, Management, Pharmaceutical industry, Mindset

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Key Points: 
  • TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.
  • Mindset entered 2023 with a robust pipeline of novel psychedelic-inspired drug candidates advancing towards first-in-human clinical trials.
  • Mindset is planning to initiate human trials of its novel and patentable prodrug of psilocin, MSP-1014, shortly.
  • In light of the success of its psychedelic therapeutic programs, Mindset is shifting its drug discovery efforts in a new complementary direction.

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Retrieved on: 
Wednesday, October 5, 2022
FSE, CSO, Development, IND, Family II, Otsuka Pharmaceutical, LLC, Patient, Mental health, Treatment, Drug discovery, CSE, CEO, CNS, Patent, Psilocybin, GLOBE, USPTO, Half-life, MSET, CRO, Pharmaceutical industry, Mindset

Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.

Key Points: 
  • Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.
  • After extensively screening multiple drug candidates in preclinical studies, we were able to identify not one, but two novel drug candidates to potentially advance to clinical human trials.
  • We are delighted to have reached this major milestone in our programs development, said James Lanthier, CEO of Mindset Pharma.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

Retrieved on: 
Tuesday, August 9, 2022
CFOS, GLOBE, Cmax, BDNF, Addiction, Brain, Patent, Board, Center, Research, Ōtsuka, Pharmacology, Patient, AUC, Board of directors, Overalls, Lists of diseases, FSE, Industry, CNS, Technology, Psychiatry, United States Patent and Trademark Office, DMT, Partnership, CAMH, Safety, CSO, Otsuka Pharmaceutical, Contract research organization, CSE, Family 1, Family II, Drug discovery, Growth, Glycoside hydrolase family 4, NCE, Drug development, Mental health, Centre for Addiction and Mental Health, Health care, Invention, MSET, RATS, IP, Psilocybin, Review, Drug design, Therapy, Central nervous system, Treatment, USPTO, Pharmaceutical industry, Fine chemical, Development, Mindset

TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Key Points: 
  • TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.
  • The development of this proprietary formulation technology is yet another excellent example of the dedication and scientific innovation engine from the Mindset team.
  • At Mindset, we also understand the immense value of strategic scientific and business partnerships with industry leading experts.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders

Retrieved on: 
Wednesday, July 6, 2022
Patient, CEO, Otsuka Pharmaceutical, Treatment, Family II, FSE, Family, GLOBE, MSET, CNS, Company, CSE, Psilocybin, CSO, Development, LLC, Patent, Drug discovery, United States Patent and Trademark Office, Pharmaceutical industry, Mindset

Family 2 is included within Mindsets collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies.

Key Points: 
  • Family 2 is included within Mindsets collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds.
  • For further information on Mindset, please visit our website at www.mindsetpharma.com .

Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action Across Multiple Next Generation Psychedelic Drug Families

Retrieved on: 
Tuesday, August 10, 2021
Lists of diseases, Half-life, CEO, Safety, Company, Patient, MSET, CSE, Drug discovery, Psilocybin, Interview, DMT, Family II, FSE, GLOBE, C-type lectin domain family 4 member F, Pharmaceutical industry

The improvement in duration and efficacy/safety of our next generation compounds has meaningful implications for psychedelic-based therapy in the clinic.

Key Points: 
  • The improvement in duration and efficacy/safety of our next generation compounds has meaningful implications for psychedelic-based therapy in the clinic.
  • Furthermore, results suggested that the half-life of our compounds range from 7-90 minutes, providing a broad range of potential duration effects.
  • Based on these Family 4 results, our compounds exhibit a broad range of pharmacological diversity that differentiates this short-acting family from Mindsets psilocybin-inspired families.
  • To watch an interview of the Company's management team discuss this announcement in greater detail, please visit: https://youtu.be/d-NuUlvGmuI .